ASCO26: Abbott demonstrates MRD test benefit in TNBC recurrence

Abbott presented data from a prospective sub-study of the PARTNER trial at ASCO26, demonstrating the clinical utility of its MRD (minimal residual disease) test in predicting triple-negative breast cancer recurrence. The findings support the diagnostic value of Abbott's molecular assay in identifying patients at risk of recurrence following treatment.